IRON

SEC source: 0000947871-23-001168 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000947871-23-001168 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,724

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the exercise of stock options granted to Carl L. Gordon ("Gordon") on October 4, 2021 by Gemini Therapeutics, Inc. ("Gemini"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. ("Disc"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC ("OrbiMed Advisors") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors.

SEC source: 0000947871-23-001167 · ownership.xml · derivative · entry 6

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,724 shares

Expires 2031-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the exercise of stock options granted to Carl L. Gordon ("Gordon") on October 4, 2021 by Gemini Therapeutics, Inc. ("Gemini"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. ("Disc"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC ("OrbiMed Advisors") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors.

F6 · derivative.exercise_date: These stock options vested on October 4, 2022.

SEC source: 0000947871-23-001167 · ownership.xml · nonDerivative · entry 2

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000947871-23-001167 · ownership.xml · nonDerivative · entry 1

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,724

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the exercise of stock options granted to Carl L. Gordon ("Gordon") on October 4, 2021 by Gemini Therapeutics, Inc. ("Gemini"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. ("Disc"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC ("OrbiMed Advisors") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 8

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 727,807

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 7

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,126,125

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 11

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 806,160

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.53 to $60.17 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 10

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 806,280

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.65 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 22

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 806,160

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.53 to $60.17 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 21

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,479,686

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.53 to $60.17 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 20

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 806,280

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.65 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 19

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,479,866

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.65 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000947871-23-001147 · ownership.xml · nonDerivative · entry 8

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 727,807

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001147 · ownership.xml · nonDerivative · entry 7

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,126,125

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001154 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 224,405

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001154 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 580,207

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001154 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 897,625

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001155 · ownership.xml · nonDerivative · entry 3

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 224,405

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001155 · ownership.xml · nonDerivative · entry 2

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 580,207

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001155 · ownership.xml · nonDerivative · entry 1

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 897,625

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 281,505

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 727,907

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,126,225

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 9

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 826,709

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 8

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 826,749

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.4381 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 18

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 826,709

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 17

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,510,511

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 16

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 826,749

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.4381 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 15

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,510,571

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.4381 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000947871-23-001147 · ownership.xml · nonDerivative · entry 6

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 281,505

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001147 · ownership.xml · nonDerivative · entry 5

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 727,907

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001147 · ownership.xml · nonDerivative · entry 4

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,126,225

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 295,605

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 764,307

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-001148 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,182,425

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 7

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 830,257

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.745 to $66.32 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 6

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 836,856

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.7499 to $65.735 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 5

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 855,471

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.67 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 4

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 856,159

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.6436 to $63.3256 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 3

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 856,824

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5297 to $62.5175 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 2

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 860,979

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.51 to $61.50 inclusive.

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058708 · doc4.xml · nonDerivative · entry 1

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 861,401

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.497 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (7), (8), (9), (10) and (11).

F2 · ownership.nature: These shares are held by Atlas Venture Opportunity I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 14

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 830,257

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.745 to $66.32 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 13

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,515,834

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.745 to $66.32 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 12

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 836,856

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.7499 to $65.735 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 11

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,525,735

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.7499 to $65.735 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 10

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 855,471

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.67 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 9

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,553,659

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.67 inclusive.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-23-058707 · doc4.xml · nonDerivative · entry 8

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 856,159

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.6436 to $63.3256 inclusive.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.